Gallbladder Disease as a Side Effect of Drugs Influencing Lipid Metabolism Experience in the Coronary Drug Project
- 26 May 1977
- journal article
- clinical trial
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 296 (21), 1185-1190
- https://doi.org/10.1056/nejm197705262962101
Abstract
We analyzed data obtained during the Coronary Drug Project to discover the influence of the drugs used on the frequency of gallbladder disease. Of 2680 placebo-treated men who had had myocardial infarction, gallbladder disease developed in 69. Corresponding figures for those given 2.5 mg of estrogen, 5.0 mg of estrogen and 1.8 g of clofibrate per day were 46 of 1061, 47 of 1081 and 42 of 1051, respectively. Each treatment group differed from placebo by over twice the standard error of the difference, life-table analysis yielding P<0.05 for each drug-placebo comparison.Keywords
This publication has 20 references indexed in Scilit:
- Aspirin in coronary heart diseaseJournal of Chronic Diseases, 1976
- Prevalence of gall stones in Dundee: a necropsy study.BMJ, 1975
- RAUWOLFIA DERIVATIVES AND BREAST CANCER: A Case/control Study in Olmsted County, MinnesotaThe Lancet, 1975
- CLOFIBRATE AND GALLSTONESThe Lancet, 1975
- Factors influencing long-term prognosis after recovery from myocardial infarction—Three-year findings of the Coronary Drug ProjectJournal of Chronic Diseases, 1974
- CLINICAL RELATIONSHIPS OF GALLSTONESThe Lancet, 1971
- The Coronary Drug Project. Initial findings leading to modifications of its research protocolJAMA, 1970
- The physicochemical basis of cholesterol gallstone formation in manJournal of Clinical Investigation, 1968
- The epidemiology of gallbladder disease: Observations in the Framingham studyJournal of Chronic Diseases, 1966
- A Multiple Comparison Procedure for Comparing Several Treatments with a ControlJournal of the American Statistical Association, 1955